In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec extends and defends bid against Facet's claim of higher value

This article was originally published in Scrip

Executive Summary

Biogen Idec has extended its hostile bid for Facet Biotech by two months after the original offer expired on October 19th. By close of trading on October 15th, fewer than 1% of Facet's shareholders had tendered their shares, Biogen Idec revealed. Facet has reiterated its recommendation that shareholders reject the bid, the terms of which remain unchanged. Biogen Idec's extended tender offer closes on December 16th.

You may also be interested in...



Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

Novartis To Pay $9.7bn For The Medicines Company

Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.

Topics

Related Companies

UsernamePublicRestriction

Register

SC005103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel